Please login to the form below

Not currently logged in
Email:
Password:

abiraterone

This page shows the latest abiraterone news and features for those working in and with pharma, biotech and healthcare.

Daily Brief:  NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal

Daily Brief:  NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal

families. “We firmly believe that the clinical effectiveness demonstrated in the multinational, Phase 3 LATITUDE study, means that abiraterone plus ADT should be made available routinely to NHS patients that need

Latest news

More from news
Approximately 5 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    outperforming J&J's Zytiga [abiraterone].

  • Taking a strategic approach Taking a strategic approach

    But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen

  • Pharma deals during October 2013 Pharma deals during October 2013

    AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy

  • Interview: Cesar Rodriguez, Janssen Interview: Cesar Rodriguez, Janssen

    Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “ a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics